In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 33-38

  Thellin, Olivier ^a   Zorzi, Willy ^a   Jolois, Olivier ^a   Elmoualij, Benaïssa ^a   Duysens, Guérin ^a   Cahay, Bernard ^b   Streel, Bruno ^b   Charif, Mounia ^a   Bastin, Renaud ^a   Heinen, Ernst ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Galephar M F Research Center   (Belgium)

Author keywords

Biofilm; Clarithromycin; Cystic fibrosis; Tobramycin

Indexed keywords

CLARITHROMYCIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CULTURE MEDIUM;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG POTENTIATION; EPITHELIUM CELL; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ANIMAL; BIOFILM; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIAL VIABILITY; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CELL LINE; CELL SURVIVAL; CLARITHROMYCIN; CULTURE MEDIA; DRUG SYNERGISM; HUMANS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84934978950     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.02.010     Document Type: Article

References (18)

1. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 2007; 35:116-29.
2. Singh PK, Schaefer AL, Parsek M.R., Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407:762-4.
3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-8.
4. Periti P. Tobramycin-clinical pharmacology and chemotherapy [in Italian]. J Chemother 1996; 8 (Suppl. 1):3-30.
5. Zarogoulidis P, Papanas N, Kioumis I., Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro antiinflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68:479-503.
6. Yasuda H, Ajiki Y, Koga T., Kawada H, Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993; 37:1749-55.
7. Buyck JM, Plesiat P, Traore H., Vanderbist F, Tulkens PM, Van Bambeke F. Increased susceptibility of Pseudomonas aeruginosato macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis 2012; 55:534-42.
8. -. Cell Tissue Res 2006; 323:405-15.
9. Tsuchiya S, Yamabe M, Yamaguchi Y., Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26:171-6.
10. Nguyen HA, Denis O, Vergison A., Theunis A, Tulkens PM, Struelens M.J., et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother 2009; 53:1434-42.
11. Tré-Hardy M, Mace C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Int J Antimicrob Agents 2009; 33:40-5.
12. Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2009; 34: 370-4.
13. Bollinger N, Hassett DJ, Iglewski B.H., Costerton JW, McDermott TR. Gene expression in Pseudomonas aeruginosa: evidence of iron override effects on quorum sensing and biofilm-specific gene regulation. J Bacteriol 2001; 183: 1990-6.
14. Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and plank-tonic cultures. Int J Antimicrob Agents 2008; 31:329-36.
15. Lutz L, Pereira DC, Paiva R.M., Zavascki AP, Barth AL. Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol 2012; 12:196.
16. Hoyle BD, Costerton JW. Transient exposure to a physiologically-relevant concentration of calcium confers tobramycin resistance upon sessile cells of Pseudomonas aeruginosa. FEMS Microbiol Lett 1989; 51: 339-41.
17. Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013; 57:2694-704.
18. Geller DE, Pitlick WH, Nardella P.A., Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219-26.